Oruka Therapeutics to Present at Multiple November Investor Conferences
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA) will present at multiple investor conferences in November 2025, providing updates on its clinical-stage biologics for chronic skin diseases including plaque psoriasis.
Scheduled presentations: Guggenheim Healthcare Innovation on Nov 10, 2025 at 9:00 AM ET; Stifel 2025 Healthcare on Nov 11, 2025 at 4:40 PM ET; and Jefferies Global Healthcare on Nov 18, 2025 at 2:00 PM GMT. A webcast and replay will be available on Oruka's investor events website.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, ORKA gained 0.62%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $1.43B at that time.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Monday, November 10th, 2025
Time: 9:00AM ET
Stifel 2025 Healthcare Conference
Date: Tuesday, November 11th, 2025
Time: 4:40PM ET
Jefferies Global Healthcare Conference
Date: Tuesday, November 18th, 2025
Time: 2:00PM GMT
A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
When will Oruka Therapeutics (ORKA) present at the Guggenheim Healthcare Innovation Conference?
What time is Oruka Therapeutics (ORKA) scheduled to speak at the Stifel 2025 Healthcare Conference?
When is Oruka Therapeutics (ORKA) presenting at the Jefferies Global Healthcare Conference?
Where can investors watch Oruka Therapeutics (ORKA) presentations and replays in November 2025?
What topics will Oruka Therapeutics (ORKA) cover at the November 2025 investor conferences?
How can investors access the live Oruka (ORKA) webcast during the conference dates in November 2025?
